Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155


Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network.

Potter JS, Chakrabarti A, Domier CP, Hillhouse MP, Weiss RD, Ling W.

J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S80-6. doi: 10.1016/j.jsat.2009.12.007.


Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.


Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, McCarty D, Reid MS, Brown LS Jr, Maslansky R, Winhusen T, Babcock D, Brigham G, Muir J, Orr D, Buchan BJ, Horton T, Ling W.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):28-36. doi: 10.1016/j.drugalcdep.2008.06.016. Epub 2008 Sep 20.


Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.

Rosenblum A, Cruciani RA, Strain EC, Cleland CM, Joseph H, Magura S, Marsch LA, McNicholas LF, Savage SR, Sundaram A, Portenoy RK.

J Opioid Manag. 2012 Nov-Dec;8(6):369-82. doi: 10.5055/jom.2012.0137.


Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.


Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.

Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA.

J Addict Med. 2012 Dec;6(4):274-9. doi: 10.1097/ADM.0b013e31826d1df3.


Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.

McCormick Z, Chu SK, Chang-Chien GC, Joseph P.

Pain Med. 2013 Aug;14(8):1187-91. doi: 10.1111/pme.12135. Epub 2013 May 3.


Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.

Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS.

Addiction. 2016 May;111(5):874-82. doi: 10.1111/add.13259. Epub 2016 Jan 26.


Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.

Renzelli CM, Capretto NA.

J Addict Dis. 2006;25(3):97-104.


Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.

Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD.

Drug Alcohol Depend. 2010 Mar 1;107(2-3):253-6. doi: 10.1016/j.drugalcdep.2009.10.014. Epub 2009 Nov 30.


Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

Baker JR, Best AM, Pade PA, McCance-Katz EF.

Ann Pharmacother. 2006 Mar;40(3):392-6. Epub 2006 Feb 28.


Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.

Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA.

Am J Addict. 2013 May-Jun;22(3):212-7. doi: 10.1111/j.1521-0391.2012.00327.x.


A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group.

Addiction. 2005 Aug;100(8):1090-100. Erratum in: Addiction. 2006 Sep;101(9):1374.


Tramadol dependence: treatment with buprenorphine/naloxone.

Ritvo JI, Koonce R, Thurstone CC, Causey HL 3rd.

Am J Addict. 2007 Jan-Feb;16(1):67-8. No abstract available.


Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD.

Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7.


Sublingual buprenorphine is effective in the treatment of chronic pain syndrome.

Malinoff HL, Barkin RL, Wilson G.

Am J Ther. 2005 Sep-Oct;12(5):379-84.


Acute pain management in opioid-tolerant patients: a growing challenge.

Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE.

Anaesth Intensive Care. 2011 Sep;39(5):804-23. Review.


Participant characteristics and buprenorphine dose.

Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):453-9. doi: 10.3109/00952990.2011.596974.


Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.

Sullivan JG, Webster L.

Clin Ther. 2015 May 1;37(5):1064-75. doi: 10.1016/j.clinthera.2015.02.027. Epub 2015 Mar 29.


In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.

[No authors listed]

Med Lett Drugs Ther. 2013 Oct 14;55(1427):83. No abstract available.


Supplemental Content

Support Center